NCT02470585 · ADVERSE EVENTS

Adverse events

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · Source last updated 2024-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was 81.7 months for the Placebo + Carboplatin + Paclitaxel -> Placebo group, 81.2 months for the Veliparib + Carboplatin + Paclitaxel -> Placebo group, and 81.1 months for the Veliparib + Carboplatin + Paclitaxel -> Veliparib group.
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Placebo + Carboplatin + Paclitaxel -> Placebo Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve (AUC) of 6 milligrams per milliliter per minute (mg/mL/min) every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.	143 / 375	369 / 375	228 / 375
Veliparib + Carboplatin + Paclitaxel -> Placebo Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.	130 / 383	375 / 383	234 / 383
Veliparib + Carboplatin + Paclitaxel -> Veliparib Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received single-agent\\ veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.	146 / 382	376 / 382	209 / 382

Group identifiers: EG000: Placebo + Carboplatin + Paclitaxel -> Placebo · EG001: Veliparib + Carboplatin + Paclitaxel -> Placebo · EG002: Veliparib + Carboplatin + Paclitaxel -> Veliparib

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
4
num At Risk
375
num Events
4
group Id
EG001
num Affected
13
num At Risk
383
num Events
14
group Id
EG002
num Affected
14
num At Risk
382
num Events
18
term
ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
APLASTIC ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
BONE MARROW FAILURE
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
9
num At Risk
375
num Events
10
group Id
EG001
num Affected
19
num At Risk
383
num Events
20
group Id
EG002
num Affected
15
num At Risk
382
num Events
17
term
FEBRILE NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
1
num At Risk
383
num Events
1
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
LEUKOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
6
num At Risk
375
num Events
9
group Id
EG001
num Affected
16
num At Risk
383
num Events
22
group Id
EG002
num Affected
12
num At Risk
382
num Events
16
term
NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
3
num At Risk
375
num Events
3
group Id
EG001
num Affected
9
num At Risk
383
num Events
12
group Id
EG002
num Affected
10
num At Risk
382
num Events
20
term
THROMBOCYTOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
ACUTE CORONARY SYNDROME
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
3
num At Risk
375
num Events
3
group Id
EG001
num Affected
1
num At Risk
383
num Events
2
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
ATRIAL FIBRILLATION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
MYOCARDIAL INFARCTION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
2
num At Risk
383
num Events
2
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
PALPITATIONS
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
STRESS CARDIOMYOPATHY

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
191
num At Risk
375
num Events
514
group Id
EG001
num Affected
232
num At Risk
383
num Events
603
group Id
EG002
num Affected
226
num At Risk
382
num Events
672
term
ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
89
num At Risk
375
num Events
223
group Id
EG001
num Affected
87
num At Risk
383
num Events
261
group Id
EG002
num Affected
114
num At Risk
382
num Events
333
term
LEUKOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
15
num At Risk
375
num Events
28
group Id
EG001
num Affected
15
num At Risk
383
num Events
20
group Id
EG002
num Affected
26
num At Risk
382
num Events
57
term
LYMPHOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
247
num At Risk
375
num Events
673
group Id
EG001
num Affected
266
num At Risk
383
num Events
881
group Id
EG002
num Affected
273
num At Risk
382
num Events
848
term
NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
119
num At Risk
375
num Events
266
group Id
EG001
num Affected
216
num At Risk
383
num Events
630
group Id
EG002
num Affected
209
num At Risk
382
num Events
735
term
THROMBOCYTOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
32
num At Risk
375
num Events
33
group Id
EG001
num Affected
19
num At Risk
383
num Events
22
group Id
EG002
num Affected
27
num At Risk
382
num Events
27
term
VISION BLURRED
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
45
num At Risk
375
num Events
55
group Id
EG001
num Affected
48
num At Risk
383
num Events
54
group Id
EG002
num Affected
34
num At Risk
382
num Events
39
term
ABDOMINAL DISTENSION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
114
num At Risk
375
num Events
163
group Id
EG001
num Affected
105
num At Risk
383
num Events
143
group Id
EG002
num Affected
118
num At Risk
382
num Events
162
term
ABDOMINAL PAIN
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
29
num At Risk
375
num Events
38
group Id
EG001
num Affected
18
num At Risk
383
num Events
24
group Id
EG002
num Affected
29
num At Risk
382
num Events
37
term
ABDOMINAL PAIN UPPER
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
157
num At Risk
375
num Events
203
group Id
EG001
num Affected
177
num At Risk
383
num Events
241
group Id
EG002
num Affected
165
num At Risk
382
num Events
228
term
CONSTIPATION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
149
num At Risk
375
num Events
248
group Id
EG001
num Affected
137
num At Risk
383
num Events
228
group Id
EG002
num Affected
164
num At Risk
382
num Events
255
term
DIARRHOEA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
19
num At Risk
375
num Events
20
group Id
EG001
num Affected
10
num At Risk
383
num Events
12
group Id
EG002
num Affected
22
num At Risk
382
num Events
23
term
DRY MOUTH

Complete source fields

event Groups

deaths Num Affected
228
deaths Num At Risk
375
description
Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve (AUC) of 6 milligrams per milliliter per minute (mg/mL/min) every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
EG000
other Num Affected
369
other Num At Risk
375
serious Num Affected
143
serious Num At Risk
375
title
Placebo + Carboplatin + Paclitaxel -> Placebo
deaths Num Affected
234
deaths Num At Risk
383
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
EG001
other Num Affected
375
other Num At Risk
383
serious Num Affected
130
serious Num At Risk
383
title
Veliparib + Carboplatin + Paclitaxel -> Placebo
deaths Num Affected
209
deaths Num At Risk
382
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received single-agent\\ veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.
id
EG002
other Num Affected
376
other Num At Risk
382
serious Num Affected
146
serious Num At Risk
382
title
Veliparib + Carboplatin + Paclitaxel -> Veliparib

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
191
num At Risk
375
num Events
514
group Id
EG001
num Affected
232
num At Risk
383
num Events
603
group Id
EG002
num Affected
226
num At Risk
382
num Events
672
term
ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
89
num At Risk
375
num Events
223
group Id
EG001
num Affected
87
num At Risk
383
num Events
261
group Id
EG002
num Affected
114
num At Risk
382
num Events
333
term
LEUKOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
15
num At Risk
375
num Events
28
group Id
EG001
num Affected
15
num At Risk
383
num Events
20
group Id
EG002
num Affected
26
num At Risk
382
num Events
57
term
LYMPHOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
247
num At Risk
375
num Events
673
group Id
EG001
num Affected
266
num At Risk
383
num Events
881
group Id
EG002
num Affected
273
num At Risk
382
num Events
848
term
NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
119
num At Risk
375
num Events
266
group Id
EG001
num Affected
216
num At Risk
383
num Events
630
group Id
EG002
num Affected
209
num At Risk
382
num Events
735
term
THROMBOCYTOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
32
num At Risk
375
num Events
33
group Id
EG001
num Affected
19
num At Risk
383
num Events
22
group Id
EG002
num Affected
27
num At Risk
382
num Events
27
term
VISION BLURRED
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
45
num At Risk
375
num Events
55
group Id
EG001
num Affected
48
num At Risk
383
num Events
54
group Id
EG002
num Affected
34
num At Risk
382
num Events
39
term
ABDOMINAL DISTENSION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
114
num At Risk
375
num Events
163
group Id
EG001
num Affected
105
num At Risk
383
num Events
143
group Id
EG002
num Affected
118
num At Risk
382
num Events
162
term
ABDOMINAL PAIN
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
29
num At Risk
375
num Events
38
group Id
EG001
num Affected
18
num At Risk
383
num Events
24
group Id
EG002
num Affected
29
num At Risk
382
num Events
37
term
ABDOMINAL PAIN UPPER
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
157
num At Risk
375
num Events
203
group Id
EG001
num Affected
177
num At Risk
383
num Events
241
group Id
EG002
num Affected
165
num At Risk
382
num Events
228
term
CONSTIPATION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
149
num At Risk
375
num Events
248
group Id
EG001
num Affected
137
num At Risk
383
num Events
228
group Id
EG002
num Affected
164
num At Risk
382
num Events
255
term
DIARRHOEA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
19
num At Risk
375
num Events
20
group Id
EG001
num Affected
10
num At Risk
383
num Events
12
group Id
EG002
num Affected
22
num At Risk
382
num Events
23
term
DRY MOUTH

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
4
num At Risk
375
num Events
4
group Id
EG001
num Affected
13
num At Risk
383
num Events
14
group Id
EG002
num Affected
14
num At Risk
382
num Events
18
term
ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
APLASTIC ANAEMIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
BONE MARROW FAILURE
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
9
num At Risk
375
num Events
10
group Id
EG001
num Affected
19
num At Risk
383
num Events
20
group Id
EG002
num Affected
15
num At Risk
382
num Events
17
term
FEBRILE NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
1
num At Risk
383
num Events
1
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
LEUKOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
6
num At Risk
375
num Events
9
group Id
EG001
num Affected
16
num At Risk
383
num Events
22
group Id
EG002
num Affected
12
num At Risk
382
num Events
16
term
NEUTROPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
3
num At Risk
375
num Events
3
group Id
EG001
num Affected
9
num At Risk
383
num Events
12
group Id
EG002
num Affected
10
num At Risk
382
num Events
20
term
THROMBOCYTOPENIA
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
ACUTE CORONARY SYNDROME
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
3
num At Risk
375
num Events
3
group Id
EG001
num Affected
1
num At Risk
383
num Events
2
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
ATRIAL FIBRILLATION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
1
num At Risk
382
num Events
1
term
MYOCARDIAL INFARCTION
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
0
num At Risk
375
num Events
0
group Id
EG001
num Affected
2
num At Risk
383
num Events
2
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
PALPITATIONS
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA 26.0
stats
group Id
EG000
num Affected
1
num At Risk
375
num Events
1
group Id
EG001
num Affected
0
num At Risk
383
num Events
0
group Id
EG002
num Affected
0
num At Risk
382
num Events
0
term
STRESS CARDIOMYOPATHY

time Frame

All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was 81.7 months for the Placebo + Carboplatin + Paclitaxel -> Placebo group, 81.2 months for the Veliparib + Carboplatin + Paclitaxel -> Placebo group, and 81.1 months for the Veliparib + Carboplatin + Paclitaxel -> Veliparib group.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice